The genetic basis, mechanism, and inheritance of this condition are not certified in this packet. No genes are listed, and no statement about causes beyond the structural description of the diaphragmatic defect in the definition is supported here.

Diagnostic methods, imaging findings, and newborn screening information are not certified in this packet.

Treatment coverage, including foundational therapies, approved treatments, and management guidance, is not certified in this packet. No approved treatment records are present.

Natural history and prognosis are not certified in this packet. The MONDO definition characterizes the condition as carrying high mortality, and no further outcome information is supplied.

Certified active trial records are numerous for congenital diaphragmatic hernia. Examples in the packet include NCT06739356, a North American Fetal Therapy Network study of long-term outcomes following fetoscopic endoluminal tracheal occlusion in severe left and right congenital diaphragmatic hernia (recruiting, sponsor The University of Texas Health Science Center, Houston); NCT02596802, a study titled Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia (active not recruiting, sponsor Anthony Johnson); NCT06884423, titled Safety and Efficacy of FETO in CDH: A Phase III Trial (recruiting, sponsor Holly L Hedrick, MD); NCT07767825, a pilot trial of FETO in fetuses with severe CDH (not yet recruiting, NYU Langone Health); and NCT05213676, titled De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia (Phase 4, recruiting, The University of Texas Health Science Center, Houston). Record titles do not establish what an intervention does. Active clinical trials for this condition are listed on ClinicalTrials.gov.